The manufacturer of Becodtide® and Becloforte® pressurised Metered Dose Inhalers (pMDI) has written to healthcare professionals to announce the discontinuation of these inhalers from the third quarter in 2007.
The discontinuation will affect the following products:
- Becotide 50microgram pMDI
- Becotide 100microgram pMDI
- Becotide 200microgram pMDI
- Becoloforte 250microgram pMDI
Since the majority of beclometasone inhalers are prescribed generically this announcement is likely to affect small numbers of patients. The inhalers listed above will still be available over the next 12 months so changes in therapy can be made during routine reviews.
Action: Consideration should be given to opportunistically changing therapy to the CFC-Free alternatives because the CFC containing products will all eventually be discontinued. The MHRA advice should be followed if CFC-Free inhalers are prescribed.
|« A worthwhile read||Cervical cancer vaccine »|